These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33486592)

  • 21. Predictive value of the sFlt-1 and PlGF in women at risk for preeclampsia in the south of Vietnam.
    Nguyen TH; Bui TC; Vo TM; Tran QM; Luu LT; Nguyen TD
    Pregnancy Hypertens; 2018 Oct; 14():37-42. PubMed ID: 30527116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.
    Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships of serum placental growth factor and soluble fms-like tyrosine kinase-1 with fetal and uterine artery Doppler indices in pre-eclampsia.
    Li J; Cai A; Yuan Q; Ding H; Zhao D
    Int J Gynaecol Obstet; 2019 May; 145(2):176-181. PubMed ID: 30801711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of preeclampsia in primigravida in late first trimester using serum placental growth factor alone and by combination model.
    Agarwal R; Chaudhary S; Kar R; Radhakrishnan G; Tandon A
    J Obstet Gynaecol; 2017 Oct; 37(7):877-882. PubMed ID: 28569565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics.
    Tarasevičienė V; Grybauskienė R; Mačiulevičienė R
    Medicina (Kaunas); 2016; 52(6):349-353. PubMed ID: 27940029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Placental growth factor, soluble fms-like tyrosine kinase 1 and progesterone as diagnostic biomarkers for ectopic pregnancy and missed abortion.
    Martínez-Ruiz A; Sarabia-Meseguer MD; Pérez-Fornieles J; Vílchez JA; Tovar-Zapata I; Noguera-Velasco JA
    Clin Biochem; 2014 Jun; 47(9):844-7. PubMed ID: 24699433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
    Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
    Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)/PlGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin.
    Navaratnam K; Abreu P; Clarke H; Jorgensen A; Alfirevic A; Alfirevic Z
    J Matern Fetal Neonatal Med; 2019 Jan; 32(2):179-187. PubMed ID: 28851242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenic profile and smoking in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
    Jääskeläinen T; Suomalainen-König S; Hämäläinen E; Pulkki K; Romppanen J; Heinonen S; Laivuori H;
    Ann Med; 2017 Nov; 49(7):593-602. PubMed ID: 28537456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of first-trimester placenta growth factor concentration to predict hypertensive disorders of pregnancy in a low-risk Asian population.
    Kumar M; Sharma K; Singh S; Singh R; Singh A; Bhattacharjee J
    Int J Gynaecol Obstet; 2017 Dec; 139(3):301-306. PubMed ID: 28815596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Angiogenic factors can be used when pre-eclampsia is suspected].
    Andrea MK; Lykke JA
    Ugeskr Laeger; 2015 May; 177(22):V11140638. PubMed ID: 26027672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?
    Myatt L; Clifton RG; Roberts JM; Spong CY; Wapner RJ; Thorp JM; Mercer BM; Peaceman AM; Ramin SM; Carpenter MW; Sciscione A; Tolosa JE; Saade G; Sorokin Y; Anderson GD;
    BJOG; 2013 Sep; 120(10):1183-91. PubMed ID: 23331974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First trimester serum placental growth factor and hyperglycosylated human chorionic gonadotropin are associated with pre-eclampsia: a case control study.
    Keikkala E; Koskinen S; Vuorela P; Laivuori H; Romppanen J; Heinonen S; Stenman UH
    BMC Pregnancy Childbirth; 2016 Nov; 16(1):378. PubMed ID: 27887594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preeclampsia and superimposed preeclampsia: The same disease? The role of angiogenic biomarkers.
    Costa RA; Hoshida MS; Alves EA; Zugaib M; Francisco RP
    Hypertens Pregnancy; 2016 May; 35(2):139-49. PubMed ID: 26930132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating levels of angiogenic factors and their association with preeclampsia among pregnant women at Mulago National Referral Hospital in Uganda.
    Nabweyambo S; Sande OJ; McGovern N; Bwanga F; Ssekagiri A; Keesiga A; Adroma M; Wasswa R; Atuheirwe M; Namugenyi J; Castelnuovo B; Nakimuli A
    PLoS One; 2021; 16(5):e0251227. PubMed ID: 34010327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association between placenta-associated circulating biomarkers and composite adverse delivery outcome of a likely placental cause in healthy post-date pregnancies.
    Bowe S; Mitlid-Mork B; Georgieva A; Gran JM; Redman CWG; Staff AC; Sugulle M
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1893-1901. PubMed ID: 34212381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study.
    Dröge LA; Perschel FH; Stütz N; Gafron A; Frank L; Busjahn A; Henrich W; Verlohren S
    Hypertension; 2021 Feb; 77(2):461-471. PubMed ID: 33280406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.